# Omalizumab to Treat Hyper-IgE (Job's) Syndrome

> **NCT00260702** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1 (actual)

## Conditions studied

- Hyper-IgE Syndrome
- Job's Syndrome

## Interventions

- **DRUG:** Omalizumab (Xolair)

## Key facts

- **NCT ID:** NCT00260702
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-24
- **Primary completion:** 2010-03-19
- **Final completion:** 2010-03-19
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00260702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00260702, "Omalizumab to Treat Hyper-IgE (Job's) Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00260702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*